Navigation Links
Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients

mucositis-stomatitis (93%/94%), acneform rash (87%/10%), radiation dermatitis (86%/90%), weight loss (84%/72%), xerostomia (72%/71%), dysphagia (65%/63%), asthenia (56%/49%), nausea (49%/37%), constipation (35%/30%) and vomiting (29%/23%). The most common adverse events seen in patients with carcinomas of the head and neck receiving ERBITUX as a single agent (N=103) were acneform rash (76%), asthenia (45%), pain (28%), fever (27%) and weight loss (27%).

The most common adverse events seen in patients with mCRC receiving ERBITUX with irinotecan (n=354) or ERBITUX as a single agent (n=420) were acneform rash (88%/90%), asthenia/malaise (73%/48%), diarrhea (72%/25%), nausea (55%/29%), abdominal pain (45%/26%), vomiting (41%/25%), fever (34%/27%), constipation (30%/26%), and headache (14%/26%).

About ImClone Systems

ImClone Systems Incorporated is committed to advancing oncology care by developing a portfolio of targeted biologic treatments designed to address the medical needs of patients with a variety of cancers. The Company's research and development programs include growth factor blockers and angiogenesis inhibitors. ImClone Systems' strategy is to become a fully integrated biopharmaceutical company, taking its development programs from the research stage to the market. ImClone Systems' headquarters and research operations are located in New York City, with additional administration and manufacturing facilities in Branchburg, New Jersey.

Certain matters discussed in this news release may constitute forward- looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Although the company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions it can give no assurance that its expectations will be achieved. Forward-looking information is subject to certain risks, trends and uncertainties that could cause actual resu
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
2. YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets Primary Endpoint in Patients with Post-Surgical Pain
3. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
4. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:4/27/2015)... 2015 Harwood Feffer LLP ( www.hfesq.com ) ... of Aerie Pharmaceuticals, Inc. ("Aerie" or the "Company") (NASDAQ: ... its fiduciary duties to shareholders. On April ... results from its first Phase 3 registration trial of ... in the trial, Rhopressa failed to meet its primary ...
(Date:4/27/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/t2mvbz/endoscopy_global ... "Endoscopy Global Market - Forecast to 2020" ... http://photos.prnewswire.com/prnh/20130307/600769) , , ,The global endoscopy market is ... growing at around 7.0% CAGR from 2014 to ... are aging population, increase in cancer, diabetes, and ...
(Date:4/27/2015)... April 27, 2015 Vermillion, Inc. ... gynecologic disease, announced today it will report ... market close on Monday, May 11, 2015, ... webcast at 4:30pm Eastern.Conference Call & Webcast: ... Pacific Domestic: , 888-556-4997International: , 719-457-2628Conference ID: ...
Breaking Medicine Technology:Harwood Feffer LLP Announces Investigation of Aerie Pharmaceuticals, Inc. 2Endoscopy Global Market - Forecast to 2020: Market is expected to reach approximately $43 billion with Johnson and Johnson, Olympus and Covidien Dominating 2Endoscopy Global Market - Forecast to 2020: Market is expected to reach approximately $43 billion with Johnson and Johnson, Olympus and Covidien Dominating 3
... Va., Nov. 10, 2011 Primary healthcare distributors continue ... navigating economic, regulatory and business climate challenges in the ... in the U.S. Healthcare Industry released by the ... the non-profit research foundation of the Healthcare Distribution Management ...
... SKILLMAN, N.J., Nov. 10, 2011 ConvaTec Healthcare today announced that ... 15, 2011. David Johnson, CEO and George Kegler, CFO will host ... telephone. Questions and answers will follow. To participate ... 701-0354. To participate in the conference internationally, dial ...
Cached Medicine Technology:Pharmaceutical Distributors Continue to Deliver Operational Efficiencies and Value to U.S. Healthcare System Amidst Economic and Regulatory Challenges 2Pharmaceutical Distributors Continue to Deliver Operational Efficiencies and Value to U.S. Healthcare System Amidst Economic and Regulatory Challenges 3Pharmaceutical Distributors Continue to Deliver Operational Efficiencies and Value to U.S. Healthcare System Amidst Economic and Regulatory Challenges 4ConvaTec Healthcare Announces 2011 Third Quarter Earnings Call 2
(Date:4/27/2015)... MN (PRWEB) April 27, 2015 Based ... Secura Consultants is one of the few insurance marketing ... in the income and asset protection markets as well ... the industry has afforded Secura Consultants the opportunity to ... to make doing business easier and quicker. , An ...
(Date:4/27/2015)... (PRWEB) April 27, 2015 According to ... and Craniofacial Research), after chronic back pain, TMJ disorders ... resulting in pain and disability. In addition, the report ... percent of the population, costing an estimated 4 billion ... million Americans suffering from seemingly unrelated symptoms such as ...
(Date:4/27/2015)... 2015 The Doctors on Liens ... of personal injury attorneys with the best doctors working on ... steady growth throughout their history and that trend continues with ... and his team in the Tujunga / Sunland ... massage therapist, patients can find comprehensive care and detailed documentation ...
(Date:4/27/2015)... 2015 TayganPoint Consulting Group, a ... announce their sponsorship of Girls on the Run ... on the Run is a youth development program ... The program is delivered through an interactive curriculum ... to develop the whole girl – physically, mentally, ...
(Date:4/27/2015)... New York, NY (PRWEB) April 27, 2015 ... Jimmy Buffett tickets at the Alpine Valley Music ... in the Elkhart, Wisconsin and Albuquerque, New Mexico area ... in their neck of the woods. Buffett will ... News in Wisconsin. His tour stops during the ...
Breaking Medicine News(10 mins):Health News:Simplified Solutions Now Makes Disability Insurance Business With Secura Consultants Even Easier! 2Health News:Dentist in Graham NC Reveals that a Jaw Disorder May Be the Cause of Chronic Headaches and Back Pain 2Health News:Prominent Doctors with Distinguished Backgrounds Join Doctors on Liens in Tujunga 2Health News:TayganPoint Consulting Group Announces Sponsorship of Girls on the Run 2Health News:Cheap Jimmy Buffett Tickets at Alpine Valley Music Theatre in Elkhorn, WI and at Isleta Amphitheater in Albuquerque, NM Now on Sale at TicketDown.com 2
... and format for its “OneMedForum 2009” finance ... in San Francisco at the Sir Francis ... and disrupters” affecting each of the following ... System and Neurostimulation; Cardiology; Urology and Sexual ...
... Farms, Inc.,(OTC Bulletin Board: USFM), a diversified commercial ... Network (OTCFN), a division of,National Financial Communications Corp. ... The OTCFN Report details US Farms, Inc.,s current ... growth and,management team. Interested parties can download ...
... Genaera Corporation (Nasdaq: GENR ) today announced ... to present at the 2008 RBC Capital Markets Healthcare Conference. ... discussion of obesity, entitled, "Shrinking The Obesity Epidemic," and will ... York on Wednesday, December 11 at 11:00 a.m. ET. , ...
... WASHINGTON, Dec. 4 Stem cells derived from bone marrow ... disease called epidermolysis bullosa (EB), a disorder characterized by extraordinarily ... Blood , the official journal of the American Society of ... bullosa is a disorder characterized by extraordinarily fragile skin and ...
... the Nation in Giving as Demand for Nonprofit Services Peaks ... More than half of Coloradans report that they will ... during the economic downturn, according to " Generous Colorado: Why ... which reflects data from surveys conducted October 2008. With demand ...
... Empowerment Fund by purchasing the Green Bracelet at www.simmonsjewelryco.com , ... The Diamond Empowerment Fund (D.E.F.), Hearst Magazines, and ... exclusive "Empowerment for Africa" dinner held at Hearst Tower in ... co-founder Russell Simmons and special guests including ...
Cached Medicine News:Health News: OneMedPlace announces panels for "OneMedForum 2009: Disrupters and Drivers in Eight Areas of Medical Technology" -- CEOs and investors to meet in unique format of focused sessions 2Health News:OTC Financial Network Issues Corporate Profile on US Farms, Inc. 2Health News:OTC Financial Network Issues Corporate Profile on US Farms, Inc. 3Health News:Genaera to Participate in Obesity Panel at RBC Capital Markets Healthcare Conference 2Health News:Bone Marrow-Derived Stem Cells May Offer Novel Therapeutic Option for Skin Disorder 2Health News:Bone Marrow-Derived Stem Cells May Offer Novel Therapeutic Option for Skin Disorder 3Health News:Bone Marrow-Derived Stem Cells May Offer Novel Therapeutic Option for Skin Disorder 4Health News:Economy Doesn't Dampen Colorado's Giving Spirit According to Statewide Giving and Volunteering Study 2Health News:Economy Doesn't Dampen Colorado's Giving Spirit According to Statewide Giving and Volunteering Study 3Health News:Economy Doesn't Dampen Colorado's Giving Spirit According to Statewide Giving and Volunteering Study 4Health News:On World AIDS Day, Russell Simmons and Special Guests Attended 'Empowerment for Africa' Dinner 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: